Pfizer has extended its strategic collaboration with Flatiron Health, a healthcare technology and services company, to further integrate and increase the use of real-world data in its targeted cancer medicines development.

Under the agreement, Pfizer is allowed to draw on de-identified, real-world datasets and analytical expertise from Flatiron Health, and are used in developing strategies for various clinical development projects across major tumour types.

Pfizer chief development officer and executive vice president Rod MacKenzie said: “Real-world data and evidence, and the technologies that capture and analyze them, are increasingly valuable ways for us to improve medicines development.

“They can augment the data we collect in traditional trials and enable greater efficiency and effectiveness in our clinical trial design and operations. We are pleased to expand our relationship with Flatiron Health as we continue to work with leading technology companies and transform clinical trials to better deliver breakthroughs to patients.”

Details of the Pfizer and Flatiron Health expanded strategic collaboration

The collaboration between Pfizer and Flatiron Health was first established in 2014, and as part of a regulatory submission for breast cancer medicines, the companies have expanded collaboration to jointly work on integrating real-world evidence.

The expanded collaboration is expected to be overseen by a Joint Steering Committee that sets strategic objectives, and guides identification and execution of projects in support of the objectives.

Under the collaboration, the companies would work on datasets from tumour types including non-small cell lung cancer (NSCLC) and colorectal cancer (CRC).

In addition, they would explore appropriate venues to share information from the research projects, and application of real-world data, with the scientific and healthcare communities to further explore the role of real-world evidence in regulatory decision making.

Flatiron Health president and co-founder Zach Weinberg said: “This collaboration is geared toward uncovering valuable insights to inform clinical development within Pfizer’s oncology portfolio, as well as identifying future areas of collaboration that will evolve the role of real-world evidence in bringing innovative cancer treatments to patients.

“We believe that the use of real-world evidence holds the potential to significantly accelerate cancer research, and we are proud to expand our relationship with Pfizer Oncology, a leader in this space.”